2022
Cardiac magnetic resonance for prophylactic implantable-cardioverter defibrillator therapy international study: prognostic value of cardiac magnetic resonance-derived right ventricular parameters substudy
Al’Aref S, Altibi A, Malkawi A, Mansour M, Baskaran L, Masri A, Rahmouni H, Abete R, Andreini D, Aquaro G, Barison A, Bogaert J, Camastra G, Carigi S, Carrabba N, Casavecchia G, Censi S, Cicala G, Conte E, De Cecco C, De Lazzari M, Di Giovine G, Di Roma M, Dobrovie M, Focardi M, Gaibazzi N, Gismondi A, Gravina M, Guglielmo M, Lanzillo C, Lombardi M, Lorenzoni V, Lozano-Torres J, Margonato D, Martini C, Marzo F, Masci P, Masi A, Memeo R, Moro C, Mushtaq S, Nese A, Palumbo A, Pavon A, Pedrotti P, Pepi M, Marra M, Pica S, Pradella S, Presicci C, Rabbat M, Raineri C, Rodriguez-Palomares J, Sbarbati S, Schoepf U, Squeri A, Sverzellati N, Symons R, Tat E, Timpani M, Todiere G, Valentini A, Varga-Szemes A, Volpe A, Fusini L, Guaricci A, Schwitter J, Pontone G. Cardiac magnetic resonance for prophylactic implantable-cardioverter defibrillator therapy international study: prognostic value of cardiac magnetic resonance-derived right ventricular parameters substudy. European Heart Journal - Cardiovascular Imaging 2022, 24: 472-482. PMID: 35792682, PMCID: PMC10029842, DOI: 10.1093/ehjci/jeac124.Peer-Reviewed Original ResearchConceptsRight ventricular systolic dysfunctionCardiac magnetic resonanceAll-cause mortalityPredictor of all-cause mortalityRV ejection fractionPrognostic valueEjection fractionSystolic dysfunctionHeart failureQuantitative assessment of RV functionMean left ventricular ejection fractionAssessment of RV functionBaseline cardiac magnetic resonanceRV systolic dysfunctionRV systolic functionMedian follow-upNormal renal functionVentricular systolic dysfunctionVentricular ejection fractionReduced ejection fractionKaplan-Meier curvesRV functionNYHA III/IVSystolic functionRenal dysfunction
2019
Perioperative Stroke in Carotid Artery Stenting as a Surrogate Marker and Predictor for 30-day Postprocedural Mortality - A Pooled Analysis of 156,000 Patients with Carotid Artery Disease.
Altibi A, Saca E, Dhillon H, Thirumala P. Perioperative Stroke in Carotid Artery Stenting as a Surrogate Marker and Predictor for 30-day Postprocedural Mortality - A Pooled Analysis of 156,000 Patients with Carotid Artery Disease. Neurology India 2019, 67: 1423-1428. PMID: 31857527, DOI: 10.4103/0028-3886.273642.Peer-Reviewed Original ResearchConceptsPredicting 30-day mortalityCarotid artery stenosisTransient ischemic attackPerioperative strokeCarotid endarterectomyOdds ratioOccurrence of perioperative strokeHigh-risk surgical patientsRelative riskPerioperative transient ischemic attackIncreased risk of strokeBilateral carotid diseasePooled odds ratioDetect intraoperative cerebral ischemiaSevere carotid stenosisCarotid artery stentingIntraoperative cerebral ischemiaCarotid artery diseaseCarotid stenosis patientsRisk of strokePatient ageStenosis patientsNeurophysiological monitoringPooled ORNeurological status
2018
Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysis
Vuong H, Ho A, Altibi A, Nakazawa T, Katoh R, Kondo T. Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysis. Lung Cancer 2018, 123: 76-82. PMID: 30089599, DOI: 10.1016/j.lungcan.2018.07.006.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerMET exonCell lung cancerAdvanced non-small cell lung cancerLung cancerGenetic eventsOdds ratioPulmonary sarcomatoid carcinomaMeta-analysisConfidence intervalsC-Met inhibitorsRandom-effects modelSarcomatoid carcinomaPrognostic featuresClinicopathological profileDismal survivalTargeted therapyClinicopathological implicationsGenomic alterationsAdvanced ageWeb of ScienceC-MetNon-smokersRare mutationsPatients
2017
TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups—A meta-analysis of aggregate data
Vuong H, Altibi A, Duong U, Ngo H, Pham T, Chan A, Park C, Fung K, Hassell L. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups—A meta-analysis of aggregate data. Critical Reviews In Oncology/Hematology 2017, 120: 1-9. PMID: 29198322, DOI: 10.1016/j.critrevonc.2017.09.013.Peer-Reviewed Original ResearchConceptsTelomerase reverse transcriptase promoter mutationTelomerase reverse transcriptaseIsocitrate dehydrogenase mutation statusProgression-free survivalTERT promoter mutationsIsocitrate dehydrogenase mutationPromoter mutationsIDH-mutantGlioma patientsOverall survivalTumor gradeMutation statusTelomerase reverse transcriptase mutationsAssociated with reduced OSGrade II/III tumorsWHO grade IIMeta-analysisIDH-wild typeInverse variance methodRandom-effects modelII/III tumorsTERT-mutIII tumorsPrognostic factorsPrognostic valuePrognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma—A meta‐analysis
Vuong H, Altibi A, Duong U, Hassell L. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma—A meta‐analysis. Clinical Endocrinology 2017, 87: 411-417. PMID: 28666074, DOI: 10.1111/cen.13413.Peer-Reviewed Original ResearchConceptsTERT promoter mutationsPapillary thyroid carcinomaPromoter mutationsRisk stratificationRisk stratification of papillary thyroid carcinomaAssociated with increased tumor aggressivenessManagement of papillary thyroid carcinomaGroup of papillary thyroid carcinomasPapillary thyroid carcinoma patientsPooled estimates of odds ratiosCombination of BRAFEstimates of odds ratiosRandom-effects modelCoexisting BRAFThyroid carcinomaPrognostic implicationsTumor aggressivenessClinicopathological implicationsBRAFClinical managementConcurrent BRAFRisk groupsOdds ratioVirtual Health LibraryWeb of ScienceBRAF Mutation is Associated with an Improved Survival in Glioma—a Systematic Review and Meta-analysis
Vuong H, Altibi A, Duong U, Ngo H, Pham T, Fung K, Hassell L. BRAF Mutation is Associated with an Improved Survival in Glioma—a Systematic Review and Meta-analysis. Molecular Neurobiology 2017, 55: 3718-3724. PMID: 28534272, DOI: 10.1007/s12035-017-0599-y.Peer-Reviewed Original ResearchConceptsProgression-free survivalKaplan Meier curveOverall survivalBRAF V600EPrognostic valueBRAF mutationsGlioma patientsImproved survivalData of hazard ratioHazard ratioYoung adult gliomasImproved overall survivalMeta-analysisInverse variance methodLow grade gliomasVirtual Health LibraryPrognosis of glioma patientsRandom-effects modelPrognostic impactPrognostic factorsTumor gradeFavorable prognosisPatient ageAdult gliomasPooled HR